Arcus Biosciences CAO sells 2,827 shares at $30

Arcus Biosciences, Inc. (RCUS) reported that Chief Accounting Officer Alexander Azoy exercised a stock option for 2,827 shares of common stock at an exercise price of $15.44 per share and on the same date sold 2,827 shares at $30.00 per share.

Rhea-AI Filing Summary

Arcus Biosciences, Inc. (RCUS) reported that Chief Accounting Officer Alexander Azoy exercised a stock option for 2,827 shares of common stock at an exercise price of $15.44 per share and on the same date sold 2,827 shares at $30.00 per share. After the option exercise, Azoy holds 3,073 stock options directly, with the option expiring on January 22, 2034. The option exercises and related sale were effected under a Rule 10b5-1 trading plan.

Insider Trade Summary 10b5-1

Exercise and Sale: 2,827 shares ($41K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Azoy Alexander

Role Chief Accounting Officer

Sold 2,827 shs ($85K)

Approx. gross sale proceeds $85K

Approx. exercise cost $44K

Approx. pre-tax spread $41K

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy) F1, F3	2,827	$0.00	$0.00
Exercise	Common Stock F1, F2	2,827	$15.44	$44K
Sale	Common Stock F1, F2	2,827	$30.00	$85K

Holdings After Transaction: Stock Option (right to buy) — 3,073 contracts (Direct); Common Stock — 39,581 shares (Direct)

Footnotes (3)

1. F1. The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
2. F2. Includes the unvested portion of the Reporting Person's RSU grants.
3. F3. The option becomes exercisable in 48 equal monthly installments after January 1, 2024, subject to the Reporting Person's continued service to the Company.

Key Figures

Options exercised: 2,827 shares Exercise price: $15.44 per share Shares sold: 2,827 shares +4 more

7 metrics

Options exercised 2,827 shares Stock option exercise into common stock on August 21, 2026

Exercise price $15.44 per share Conversion price for Stock Option (right to buy) into common stock

Shares sold 2,827 shares Common stock sale on August 21, 2026

Sale price $30.00 per share Price for sale of 2,827 common shares

Options remaining after transaction 3,073 shares Total stock options held directly following the exercise

Option expiration date January 22, 2034 Expiration of the exercised stock option grant

Vesting schedule 48 equal monthly installments Option becomes exercisable in 48 monthly installments after January 1, 2024

Key Terms

Rule 10b5-1 trading plan, Stock Option (right to buy), Restricted Stock Unit, Exercise or conversion of derivative security

4 terms

Rule 10b5-1 trading plan regulatory

"The option exercises and sales ... were effected pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

Restricted Stock Unit financial

"Includes the unvested portion of the Reporting Person's RSU grants"

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

Exercise or conversion of derivative security financial

"transaction_code_description: Exercise or conversion of derivative security"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Alexander Azoy report for Arcus Biosciences (RCUS)?

Alexander Azoy reported exercising a stock option for 2,827 shares of Arcus Biosciences common stock at $15.44 per share and selling 2,827 shares at $30.00 per share on August 21, 2026, all held and transacted directly.

At what prices did the RCUS stock option exercise and sale occur?

The stock option for Arcus Biosciences (RCUS) was exercised at an exercise price of $15.44 per share. The 2,827 shares of common stock acquired from this exercise were then sold at $30.00 per share on the same date.

How many Arcus Biosciences (RCUS) options does Alexander Azoy hold after this Form 4?

Following the reported option exercise, Alexander Azoy holds 3,073 Arcus Biosciences stock options directly. These options relate to a grant that becomes exercisable in 48 equal monthly installments after January 1, 2024 and expire on January 22, 2034.

Was the RCUS insider transaction by Alexander Azoy under a Rule 10b5-1 plan?

Yes. The filing states that the option exercises and sales were effected pursuant to a Rule 10b5-1 trading plan adopted by Alexander Azoy. Such a plan pre-schedules trades, reducing the informational content of trade timing for investors.

What does the Form 4 reveal about Alexander Azoy’s RCUS equity awards?

The Form 4 shows Azoy exercised 2,827 stock options and notes that his reported common stock holdings include the unvested portion of RSU grants. The underlying option becomes exercisable in 48 equal monthly installments after January 1, 2024.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/24/2026 - 05:52 PM Accepted by SEC EDGAR 08/24/2026 - 05:52 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Azoy Alexander

(Last) (First) (Middle)

C/O ARCUS BIOSCIENCES, INC.

3928 POINT EDEN WAY

(Street)

HAYWARD CALIFORNIA 94545

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Arcus Biosciences, Inc. [ RCUS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Accounting Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/21/2026		M		2,827(1)	A	$15.44	42,408(2)	D
Common Stock	08/21/2026		S		2,827(1)	D	$30	39,581(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$15.44	08/21/2026		M			2,827(1)	(3)	01/22/2034	Common Stock	2,827	$0	3,073	D

Explanation of Responses:

1. The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

2. Includes the unvested portion of the Reporting Person's RSU grants.

3. The option becomes exercisable in 48 equal monthly installments after January 1, 2024, subject to the Reporting Person's continued service to the Company.

Remarks:

	/s/ Carolyn Tang, Attorney-in-Fact	08/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)